Potential of dihydropyrimidine dehydrogenase genotypes in personalising 5-fluorouracil therapy among colorectal cancer patients
Background: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
International Association of Therapeutic Drug Monitoring and Clinical Toxicology
2011
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/43026/ http://irep.iium.edu.my/43026/ http://irep.iium.edu.my/43026/1/potential.pdf |